, /PRNewswire/ -- Infinant Health, a privately-held company focused on changing the trajectory of human health by supporting the development and restoration of the immune system via the gut microbiome, announces additions to their advisory team: Dr. and Dr. .
Additionally, has joined the board, representing Manna Tree Partners, to help prepare the company's expansion into pharma. Infinant Health recently announced their submission for ODD status and are augmenting their team with top-tier experts to support work underway on their groundbreaking product subspecies strain, INF108, aimed at averting necrotizing enterocolitis (NEC) in premature infants. "It is with great pleasure that I announce the addition of three distinguished individuals to our team at Infinant Health.
The extensive expertise they bring in human clinical trials, coupled with their profound pharmaceutical knowledge, fortifies our resolve as we embark on the next pivotal phase of our company's evolution," stated CEO . He continued, "This strategic move underscores our commitment to pioneering advancements in the microbiome space and our dedication to excellence in therapeutic product development." Dr.
Knobil has been appointed as an to the Infinant Health Board, bringing more than 25 years of experience in pharmaceutical research and product development including global clinical research, medical affairs and patient safety in large pharma, biotech, and medtech. Dr. Knobil has strategically led research and dev.
